Loss of Tumorigenicity of Murine Colon Carcinoma MC38/0 Cell Line after Transduction with a Retroviral Vector Carrying Murine IL-12 Genes

Pajtasz-Piasecka, Elżbieta; Szyda, A.; Rossowska, J.; Krawczenko, A.; Indrová, M.; Grabarczyk, P.; Wysocki, P.; Mackiewicz, A.; Duś, D.

doi:10.14712/fb2004050010007

Fol. Biol. 2004, 50, 7-14

https://doi.org/10.14712/fb2004050010007

Loss of Tumorigenicity of Murine Colon Carcinoma MC38/0 Cell Line after Transduction with a Retroviral Vector Carrying Murine IL-12 Genes

Elżbieta Pajtasz-Piasecka¹, A. Szyda¹, J. Rossowska¹, A. Krawczenko¹, M. Indrová², P. Grabarczyk³, P. Wysocki³, A. Mackiewicz³, D. Duś¹

¹Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
²Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
³Department of Cancer Immunology, Chair of Oncology, University of Medical Sciences at Great Poland Cancer Centre, Poznań, Poland

Received November 2003
Accepted February 2004

Cells of transplantable MC38 colon carcinoma of C57BL/6 mice were adapted to growth in vitro as the MC38/0 cell line. Along the establishing process, MC38/0 cells preserved their tumorigenicity. After transduction with a retroviral vector carrying murine interleukin 12 (mIL-12) genes and further selection, stable MC38/IL-12 transductant cells were obtained. These cells produced IL-12 (approx. 2500 ng/ml /5x10⁵ cells /48 h) as evaluated in the optimized bioassay. After subcutaneous inoculation into syngeneic mice, the IL-12-modified cells demonstrated reduced tumorigenicity as compared to parental MC38/0 cells. Mice that rejected the MC38/IL-12 tumour became protected against subsequent challenge with MC38/0 cells. The obtained data indicate that the IL-12-transduced murine colon carcinoma cells could be used both as a model tumour for the study of mechanisms of anticancer immunity and/or as an adjuvant to cancer vaccines.